ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Hepatitis C virus infection in Egypt

6th Global Gastroenterologists Meeting

Hasan Ahmed El-Garem

Cairo University, Egypt

ScientificTracks Abstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X.C1.034

Abstract
Egypt has the highest prevalence of hepatitis C virus infection in the world. The prevalence of HCV viremia was estimated to be 7.3%, and 90% of them have genotype 4. Until 2007, hepatitis C virus treatment was not offered by the government. In 2007, an Egyptian National Committee for Control of Viral Hepatitis (NCCVH) has been established. Number of patients treated with PEG-INF and ribavirin was 350,000. A further step in treating HCV was FDA approval of Sofosbuvir in 2013. Egyptian government made an agreement with the manufacturer company Gilead to decrease the cost of the course for 3 months from 84000$ to 900$. New treatment protocol started in September 2014. The protocol categorized patients into 2 groups: Group 1 - Patients who were eligible to receive interferon were treated with daily Sofosbuvir (400 mg) and weightbased ribavirin plus weekly peginterferon for 12 weeks and Group 2 - Patients who were not eligible to receive interferon were treated by daily sofosbuvir (400 mg) plus weight-based ribavirin for 24 weeks. A further step in treating HCV was achieved after availability of the new drugs, daclatasvir and ritonavir boosted paritaprevir/ombitasvir in Egypt. Treatment protocol was updated in November 2015. Patients were categorized into 4 groups: 1 - Easy to treat group, was treated by the following regimen for 12 weeks; sofosbuvir (400 mg) plus daclatasvir (60 mg). 2 - Difficult to treat group, was treated by the following regimen for 12 weeks; sofosbuvir (400 mg) plus daclatasvir (60 mg) plus ribavirin (600 mg up to 1000 mg). 3 - Third regimen was for patients with post organ transplantation and patients who failed previous sofosbuvir containing regimen. These patients were treated by the following regimen for 24 weeks; sofosbuvir (400 mg) plus daclatasvir (60 mg) plus ribavirin (600 mg up to 1000 mg). 4 - Fourth regimen for patients with glomerular filtration rate less than 30 ml/min were treated by ritonavir boosted paritaprevir/ombitasvir plus ribavirin for 12 weeks. Results of treatment will be mentioned in the presentation.
Biography

Hasan Ahmed El-Garem has completed his MD from Faculty of Medicine, Cairo University and Post-doctoral studies from Amsterdam Medical Centre. He is a Professor of Gastroenterology & Hepatology at Faculty of Medicine, Cairo University. He has published more than 25 papers in reputed journals.

Email: Helgarem@yahoo.com

Top